Physician profile
Brian Roeder
NPI 1023034170
$1,125.17
in general payments reported to CMS, 2019-2025
28 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $435 · 2023: $193 · 2024: $35.91 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifenet Health | $240.92 | 2025 | Pliafx Flo, Allograft Vmis Delivery System |
| Medtronic, INC. | $111.17 | 2021-2024 | Cd Horizon Spinal System, Catalyft Pl Expandable Interbody System |
| Bone Support INC. | $89.70 | 2022 | |
| Lundbeck LLC | $60.03 | 2021-2022 | |
| Ucb, INC. | $59.49 | 2021-2022 | |
| Argenx US, INC. | $48.63 | 2022-2023 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $46.88 | 2021 | |
| Tanabe Pharma America, INC. | $35.81 | 2021-2022 | |
| Eisai INC. | $31.05 | 2021-2022 | |
| Pfizer INC. | $28.30 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $26.76 | 2023 | Libtayo |
| Averitas Pharma INC. | $24.78 | 2023 | Qutenza |
| Vertos Medical, INC. | $24.36 | 2023 | Mild Device Kit |
| Amgen INC. | $23.64 | 2022 | |
| Genzyme Corporation | $23.10 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $22.52 | 2022 | |
| Bioventus LLC | $22.12 | 2023 | Bonescalpel |
| Trevena, INC. | $22.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.57 | 2022 | |
| Merck Sharp & Dohme LLC | $20.96 | 2022 | |
| Banner Life Sciences, LLC | $19.84 | 2022 | |
| Intrinsic Therapeutics | $19.31 | 2023 | Barricaid Acd (Annular Closure Device) |
| Csl Behring | $18.90 | 2021 | |
| Abbvie INC. | $18.24 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.18 | 2023 | |
| Neurelis, INC. | $17.67 | 2024 | Valtoco |
| Lilly USA, LLC | $16.87 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Roeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.